

Esperion Therapeutics, Inc. Investor Relations Department 3891 Ranchero Drive Suite 150 Ann Arbor, MI 48108 United States

Visit IR website ☐ Sign-up for Email alerts ☐ ☐

NASDAQ: ESPR Last Trade: 73.69 Trade Time: 4:00 PM ET Apr 20, 2018 Change: -0.47 ♣ (-0.634%) Day Range 72.88 - 75.68 52-Week Range 30.95 - 82.68 Volume 293,749

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Esperion is a late-stage pharmaceutical company passionately committed to developing and commercializing complementary, nonstatin, once-daily, oral therapies to lower elevated low density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipidmodifying therapies. Bempedoic acid, a convenient, complementary, costeffective, once-daily, oral inhibitor of ATP Citrate Lyase (ACLi) brings a targeted mechanism of action to address patients unmet medical needs in a way that is "patient-friendly, physician-frie... (more)

Stock Performance



Press Releases [View all]

Apr 13, 2018

Esperion Announces Inducement Grants
Under NASDAQ Listing Rule 5635(c)(4)

Mar 27, 2018

Esperion Announces Positive Top-Line
Results from Phase 2 Study of Bempedoic
Acid Added-On to a PCSK9 Inhibitor in
Patients with Hypercholesterolemia

Mar 7, 2018

Esperion to Participate in Fireside Chat at March 2018 Investor Conferences

Mar 7, 2018

Esperion Announces Positive Top-Line
Results from First Pivotal Phase 3 Study of
Bempedoic Acid

Feb 23, 2018

Esperion Announces Inducement Grants
Under NASDAQ Listing Rule 5635(c)(4)

Financials [View all]

Fourth Quarter Financial Results

Feb 20, 2018

Annual Report (10-K)

Apr 13, 2018

Proxy Statement (DEF 14A)

Nov 7, 2017

Quarterly Report (10-Q)

Aug 8, 2017

Quarterly Report (10-Q)

May 4, 2017

Quarterly Report (10-Q)